In Massachusetts, Audax Medical, Inc. has a worldwide license from Northeastern University for new nanotechnology of a self-assembling arginine-rich peptide to add to its current tissue regeneration platform. They plan to use this new nanotech for their medical applications and tissue regeneration. The newly developed nanostructures have antimicrobial properties, but unlike antibiotics which go after specific cellular activity, the nanoparticles aim specifically for the microorganisms’ cytoplasmic membrane which limits the inflammation and infection in surrounding tissue. Mark Johanson, Audax’s CEO, told PR Newswire, “We are excited to be collaborating with Northeastern’s team of world-class researchers. This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Latest article
Bruce the dog reviews cultivated meat
In Scotland, Philip Lymbery, a journalist writing for The Scotsman has turned to his beloved pup Bruce to review Chick Bites dog treats, the...
Breaking nugget news: Japanese scientists create lab-growth chicken with circulatory system
In Tokyo, researchers have created the world’s largest, and most advanced, lab-growth chicken nugget.
Featuring “veins” that deliver nutrients and oxygen, the new nugget...
Be green on the green with biodegradable golf balls
In Vancouver, a company is selling golf balls that biodegrade in two weeks and are made from compressed corn starch, calcium carbonate, glycerin, and...